Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
Dawson said he would “retire at the appropriate time”.
“I believe this is the right time to start the transition to a new leader given the robustness of the senior team and company as a whole, which is undoubtedly stronger than ever before,” he said in a statement.
Oxford Biomedica chairman Dr Roch Doliveux said it had started searching for Dawson’s replacement to “lead the group through its next phase of growth”.
